Study of VY1706 for early Alzheimer's disease
Part of Brain & nervous system clinical trials.
This study tests an experimental treatment called VY1706 for people with early Alzheimer's disease. It aims to see if the treatment is safe and how well it works, and may help slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 80 years old (or 30 to 80 if you have a family history of early-onset Alzheimer's).
- You have been diagnosed with mild cognitive impairment or mild Alzheimer's disease.
- You have a study partner who can support you throughout the trial.
- You are generally healthy aside from your Alzheimer's diagnosis.
- You have not had a stroke, seizure, or certain heart conditions recently.
- You have not used certain Alzheimer's treatments or participated in gene therapy trials before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, VHB937, in people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow down memory loss and thinking problems.
This early-stage trial tests whether ABBV-1758, a new drug given by injection, is safe and effective for people with Alzheimer's disease. The drug targets amyloid, a protein that builds up in the brains of people with Alzheimer's.
This trial tests a vaccine that may help the immune system clear a protein linked to Alzheimer's disease. It is for people who do not have memory problems yet but have signs of the disease in their blood or brain scans.
This Phase 4 trial tests whether a medicine called sodium oligomannate (GV-971) is safe and effective for people with mild to moderate Alzheimer’s disease. It may help slow or improve memory and thinking symptoms while carefully tracking side effects.
This study tests an oral tablet (TTYP01) for people with early Alzheimer's disease. It aims to see if the drug can slow memory loss. You must have a study partner who can support you throughout the trial.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.